Reversal of Direct Oral Anticoagulants: Guidance from the Anticoagulation Forum
Recommended Citation
Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S. Reversal of Direct Oral Anticoagulants: Guidance from the Anticoagulation Forum. American journal of hematology 2019; .
Document Type
Article
Publication Date
3-27-2019
Publication Title
American journal of hematology
Abstract
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal. Non-specific prohemostatic agents such as prothrombin complex concentrate (PCC) and activated PCC have also been used for DOAC reversal. The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of DOAC reversal agents. We discuss indications for reversal, provide guidance on how the individual reversal agents should be administered, and offer suggestions for stewardship at the health system level. This article is protected by copyright. All rights reserved.
PubMed ID
30916798
ePublication
ePub ahead of print
